We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

62 hedge funds and large institutions have $1.13B invested in ARS Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

70.26% more ownership

Funds ownership: 0% → 70.26% (+70%)

Holders
62
Holders Change
+62
Holders Change %
–
% of All Funds
1.1%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.07%
New
62
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$292M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$115M
3
EC
EcoR1 Capital
California
+$84.6M
4
RCM
RA Capital Management
Massachusetts
+$58.2M
5
BC
Boxer Capital
California
+$56M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$4.07M +$2.93M +87,813 New
GPP
27
Great Point Partners
Connecticut
$3.24M +$2.34M +70,000 New
MIM
28
Monashee Investment Management
Massachusetts
$2.78M +$2M +60,000 New
MWNA
29
Marshall Wace North America
New York
$2.72M +$1.96M +58,788 New
UBS AM
30
UBS AM
Illinois
$2.67M +$1.92M +57,575 New
Vanguard Group
31
Vanguard Group
Pennsylvania
$2.32M +$1.67M +50,000 New
FCM
32
Farallon Capital Management
California
$2.21M +$1.59M +47,620 New
PVI
33
Pura Vida Investments
New York
$2.08M +$1.5M +45,000 New
Victory Capital Management
34
Victory Capital Management
Texas
$1.98M +$1.43M +42,680 New
PCM
35
Pinz Capital Management
New York
$1.87M +$1.35M +40,300 New
FM
36
Frazier Management
Washington
$1.66M +$1.19M +35,750 New
Alyeska Investment Group
37
Alyeska Investment Group
Illinois
$1.16M +$835K +25,000 New
CCM
38
CAAS Capital Management
New York
$1.16M +$835K +25,000 New
BOTOTLSJU
39
Board of Trustees of The Leland Stanford Junior University
California
$1.01M +$726K +21,740 New
ECM
40
ExodusPoint Capital Management
New York
$968K +$697K +20,882 New
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$903K +$651K +19,484 New
Geode Capital Management
42
Geode Capital Management
Massachusetts
$891K +$642K +19,230 New
Jane Street
43
Jane Street
New York
$882K +$636K +19,038 New
Citigroup
44
Citigroup
New York
$699K +$504K +15,084 New
Wellington Management Group
45
Wellington Management Group
Massachusetts
$641K +$462K +13,837 New
SG Americas Securities
46
SG Americas Securities
New York
$598K +$431K +12,900 New
TEE
47
Tibra Equities Europe
United Kingdom
$598K +$431K +12,900 New
MFS
48
Mirabella Financial Services
United Kingdom
$525K +$379K +11,340 New
Janney Montgomery Scott
49
Janney Montgomery Scott
Pennsylvania
$508K +$366K +10,957 New
ZP
50
Zimmer Partners
New York
$463K +$334K +10,000 New
1
2
3

SPRY Hedge Fund Activity: Q4 2020 in Review

62 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2020, worth a combined $1.13B.

Buyers outnumbered sellers: 62 funds opened new SPRY positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $292M.

  • 62 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $1.13B of ARS Pharmaceuticals stock for Q4 2020.
  • 62 funds opened new ARS Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +62 holders.
  • The largest ARS Pharmaceuticals buyer in Q4 2020 was OrbiMed, an estimated $292M added.

Based on aggregated 13F filings for Q4 2020.